Senti Biosciences(SNTI) - 2025 Q4 - Annual Report

Financial Transactions - The company sold purchased assets for a total consideration of $37.8 million in cash, with $18.9 million paid at closing and the remaining $18.9 million waived in connection with a private placement investment[94]. - GeneFab was provided an option to purchase up to 1,963,344 shares of common stock, valued at up to $20.0 million, at an exercise price of $10.18670, exercisable by August 7, 2026[95]. - The company will receive ten percent of the realized gains from GeneFab's parent company as part of the seller economic share agreement[96]. - An amendment to the GeneFab Framework Agreement was made, waiving the GeneFab Note Receivable and entering into an amended development and manufacturing services agreement[97]. Clinical Trials and Regulatory Approvals - The Celest Agreement includes collaboration for an investigator-initiated trial of the SENTI-301A gene circuit, with a Phase 1 clinical trial initiated in 2024[99]. - Celest Therapeutics has an exclusive option to obtain a license for SN301A, with potential aggregate payments of $156.0 million and tiered royalty payments if the option is exercised[100]. - The regulatory approval process for biologics requires substantial time and financial resources, including preclinical testing and submission of an IND to the FDA[110]. - The FDA's goal is to review standard BLA applications within ten months and priority review applications within six months after filing[124]. - Two adequate and well-controlled Phase 3 clinical trials are generally required by the FDA for BLA approval[122]. - The FDA may issue a Complete Response Letter (CRL) if the BLA is not approved in its current form, detailing deficiencies identified[126]. - Fast track designation allows for more frequent interactions with the FDA during product development and may qualify for priority review[129]. - Breakthrough therapy designation provides intensive FDA interaction and guidance beginning as early as Phase 1[130]. - Accelerated approval may be granted if the product shows an effect on a surrogate endpoint likely to predict clinical benefit[132]. - RMAT designation facilitates efficient development and expedited review for biologics intended to treat serious conditions[134]. - The FDA may require post-marketing studies to verify clinical benefits for products granted accelerated approval[132]. - The BLA submission requires a substantial application user fee unless a waiver applies[121]. - The FDA may withdraw product approval if compliance with pre- and post-marketing requirements is not maintained[128]. - On June 18, 2025, the FDA granted Orphan Drug Designation to SENTI-202 for treating relapsed/refractory hematologic malignancies, including acute myeloid leukemia[136]. - Orphan drug designation provides financial incentives such as grant funding opportunities, tax advantages, and user-fee waivers[137]. - Orphan product exclusivity prevents the FDA from approving other applications for the same indication for seven years, with exceptions for clinical superiority or supply assurance[137]. - SENTI-202 received Regenerative Medicine Advanced Therapy (RMAT) designation in December 2025, facilitating expedited review and development[140]. - The FDA has 60 calendar days to determine if a drug meets RMAT criteria after a request is made[140]. - Biologics are subject to ongoing FDA regulation, including record-keeping, adverse experience reporting, and compliance with cGMP requirements[141]. - The FDA may withdraw approval if regulatory compliance is not maintained or if new problems are discovered post-market[142]. Market and Pricing Regulations - The Affordable Care Act established an abbreviated approval pathway for biosimilars, which must demonstrate no clinically meaningful differences from reference products[147]. - A biosimilar application cannot be submitted until four years after the reference product's first FDA license, with a 12-year exclusivity period for approval[149]. - Coverage and reimbursement for new products depend on decisions made by government health authorities and private insurers, impacting pricing and profitability[151]. - The Inflation Reduction Act of 2022 reduces out-of-pocket spending cap for Medicare Part D beneficiaries from $7,050 to $2,000 starting in 2025, effectively eliminating the coverage gap[161]. - The statutory minimum rebates under the Medicaid Drug Rebate Program have increased to 23.1% for most branded drugs and 13% for generic drugs[160]. - The American Rescue Plan Act of 2021 eliminated the statutory Medicaid drug rebate cap, previously set at 100% of a drug's average manufacturer price, for certain drugs starting January 1, 2024[160]. - The Budget Control Act of 2011 mandates a 2% reduction in Medicare payments to providers per fiscal year, effective through 2031[160]. - The Right to Try Act allows certain patients to access investigational drugs without enrolling in clinical trials, but manufacturers are not obligated to provide these drugs[160]. - Increased scrutiny over drug pricing practices has led to Congressional inquiries and proposed legislation aimed at enhancing transparency and reducing prescription drug costs[159]. - States are implementing aggressive regulations to control pharmaceutical pricing, which may include price constraints and marketing cost disclosures[164]. - Future healthcare reform measures may limit federal and state government payments for healthcare products, potentially reducing demand for current and future product candidates[165]. - Any denial of coverage or reimbursement from Medicare may lead to similar outcomes from private payors, impacting revenue generation and profitability[166]. - The implementation of the IRA's Medicare drug price negotiation program is currently subject to ongoing litigation, with uncertain effects on the business[161]. International Regulations and Exclusivity - The European Union grants eight years of data exclusivity and an additional two years of market exclusivity for new chemical entities or innovative medicinal products upon receiving marketing authorization[176]. - The overall exclusivity period can extend to a maximum of 11 years if the marketing authorization holder obtains new therapeutic indications that provide significant clinical benefits within the first eight years[176]. - Orphan medicinal products receive ten years of market exclusivity, which may be reduced to six years if the product no longer meets orphan designation criteria after five years[179]. - The European Commission introduced legislative proposals in April 2023 to replace the current regulatory framework for all medicines, with amendments proposed by the European Parliament in October 2023[180]. Company Operations and Workforce - As of March 19, 2026, the company had 39 full-time employees, with 7 holding Ph.D. or M.D. degrees[188]. - The company occupies approximately 40,000 square feet of office and R&D space in South San Francisco, with a lease expiring in April 2027[190]. - A cell therapy manufacturing facility was completed in June 2023, with a sublease agreement for 92,000 square feet of manufacturing space executed in August 2023, expiring in September 2032[191]. - The company qualifies as a smaller reporting company, allowing it to provide only two years of audited financial statements[192]. - The company’s common stock began trading on the Nasdaq Global Market under the symbol "SNTI" following a merger on June 8, 2022[194]. - Failure to comply with GDPR may result in fines up to €20 million or 4% of global annual revenues, whichever is higher[187].